SM 6586

Drug Profile

SM 6586

Alternative Names: SM-6586

Latest Information Update: 14 Oct 2005

Price : $50

At a glance

  • Originator Sumitomo Pharmaceuticals
  • Class Antihypertensives
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cerebrovascular disorders; Hypertension

Most Recent Events

  • 21 Jul 2000 Discontinued-I for Hypertension and Cerebrovascular disease in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top